Patents by Inventor Ian S. Zagon

Ian S. Zagon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20010046968
    Abstract: The present invention provides that an endogenous opioid peptide, OGF, inhibits angiogenesis in vivo via acting on OGF receptor. The present inventions also provides that opioid antagonist naltrexone and naltrexone stimulated blood vessel development. Therapeutic compositions and methods for modulating angiogenesis are provided.
    Type: Application
    Filed: March 22, 2001
    Publication date: November 29, 2001
    Inventors: Ian S. Zagon, John Blebea, Patricia J. McLaughlin
  • Patent number: 6136780
    Abstract: The present invention is related to the treatment and prevention of cancer including particularly gastrointestinal cancer. More specifically, the present invention describes the use of naltrexone, naloxone and the pentapeptide growth factor [Met.sup.5 ]-enkephalin to inhibit and arrest the growth of cancer. Such efficiency has been discovered to be a consequence of the functional manipulation of the zeta (.zeta.) opioid receptor through endogenous [Met.sup.5 ]-enkephalin. This receptor has been determined to be present in growing cancers such as pancreatic and colon cancer, for example.
    Type: Grant
    Filed: March 27, 1997
    Date of Patent: October 24, 2000
    Assignee: The Penn State Research Foundation
    Inventors: Ian S. Zagon, Patricia J. McLaughlin
  • Patent number: 5426112
    Abstract: A method for regulating the growth processes in a myriad of cells, tissues, organ systems and unicellular and multicellular organisms including plants, animals and man by the administration of effective amounts of the opioid antagonists naloxone, naltrexone, their analogs, metabolites derivatives, and/or mixtures thereof. At the cellular level, the growth processes entail all mitetic events and related processes including cell proliferation, as well as cell migration and cell differentiation, and at the somatic or organismal level, anatomical, behavioral and neurological development, metamorphisis and maturation. Growth regulation can be effected in vivo and/or in vitro.
    Type: Grant
    Filed: February 23, 1993
    Date of Patent: June 20, 1995
    Assignee: Scully, Scott, Murphy & Presser, P.C.
    Inventors: Ian S. Zagon, Patricia J. McLaughlin
  • Patent number: 5266574
    Abstract: A method for regulating the growth processes in a myriad of cells, tissues, organ systems and unicellular and multicellular organisms including plants, animals and man by the administration of effective amounts of the opioid antagonists naloxone, naltrexone, their analogs, metabolites derivatives, and/or mixtures thereof. At the cellular level, the growth processes entail all mitotic events and related processes including cell proliferation, as well as cell migration and cell differentiation, and at the somatic or organismal level, anatomical, behavioral and neurological development, metamorphisis and maturation. Growth regulation can be effected in vivo and/or in vitro.
    Type: Grant
    Filed: August 6, 1991
    Date of Patent: November 30, 1993
    Assignees: Ian S. Zagon, Patricia J. McLaughlin
    Inventors: Ian S. Zagon, Patricia J. McLaughlin
  • Patent number: 4689332
    Abstract: A method for regulating the growth processes in a myriad of cells, tissues, organ systems and unicellular and multicellular organisms including plants, animals and man by the administration of effective amounts of the opioid antagonists naloxone, naltrexone, their analogs metabolites derivatives, and/or mixtures thereof. At the cellular level, the growth processes entail all mitotic events and related processes including cell proliferation, as well as cell migration and cell differentiation, and at the somatic or organismal level, anatomical, behavioral and neurological development, metamorphisis and maturation. Growth regulation can be effected in vivo and/or in vitro.
    Type: Grant
    Filed: April 9, 1984
    Date of Patent: August 25, 1987
    Assignee: Research Corporation
    Inventors: Patricia J. McLaughlin, Ian S. Zagon